BACKGROUND: Glioblastoma (GBM) is a highly aggressive astrocytoma with a dismal prognosis. Since 1976, only three chemotherapeutic agents have been approved for the treatment of GBM. Tumor-treating fields (TTFields) therapy, delivered via a noninvasive device, is a new therapy approved for use in patients with recurrent GBM and in combination with temozolomide for the treatment of newly diagnosed GBM. OBJECTIVES: This article reviews the mechanism of action and findings from preclinical and clinical studies supporting the use of TTFields for patients with newly diagnosed and recurrent GBM. METHODS: This article provides an overview of published literature on the efficacy and safety of treating GBM with TTFields. FINDINGS: For the first time in more than a decade, patients with GBM have a noninvasive treatment option that has been shown to increase progression-free survival and overall survival with minimal adverse events.
BACKGROUND:Glioblastoma (GBM) is a highly aggressive astrocytoma with a dismal prognosis. Since 1976, only three chemotherapeutic agents have been approved for the treatment of GBM. Tumor-treating fields (TTFields) therapy, delivered via a noninvasive device, is a new therapy approved for use in patients with recurrent GBM and in combination with temozolomide for the treatment of newly diagnosed GBM. OBJECTIVES: This article reviews the mechanism of action and findings from preclinical and clinical studies supporting the use of TTFields for patients with newly diagnosed and recurrent GBM. METHODS: This article provides an overview of published literature on the efficacy and safety of treating GBM with TTFields. FINDINGS: For the first time in more than a decade, patients with GBM have a noninvasive treatment option that has been shown to increase progression-free survival and overall survival with minimal adverse events.
Authors: Mario E Lacouture; Milan J Anadkat; Matthew T Ballo; Fabio Iwamoto; Suriya A Jeyapalan; Renato V La Rocca; Margaret Schwartz; Jennifer N Serventi; Martin Glas Journal: Front Oncol Date: 2020-07-28 Impact factor: 6.244